Why Insmed Stock Is Back In Focus After Q2 Earnings

Insmed (INSM) has moved back into the spotlight after second quarter 2026 earnings on 6 August. The company reported a sharply smaller net loss and raised its full year revenue guidance, which helped spark renewed investor interest.

Insmed’s recent earnings release and revenue guidance update have come after a strong 7 day share price return of 32.96% and a 90 day share price return of 26.19%. However, the year to date share price return is down 25.98% and the 3 year total shareholder return is very large, which signals that long term momentum remains strong while shorter term moves are resetting expectations.

If Insmed’s move has you looking at other opportunities in healthcare, it can be useful to see which peers are drawing interest from the market right now through the 43 healthcare AI stocks

For Insmed, the sharp revenue jump and smaller loss suggest the business is gaining traction, while the steep recent share price move points to a surge in optimism. How much of today’s valuation reflects fundamentals rather than mood swings?

Most Popular Narrative: 33.5% Undervalued

Insmed's most followed narrative pegs fair value at about $197 per share compared with the last close at $131.10, which places a lot of emphasis on future execution.

The anticipated U.S. launch of brensocatib in bronchiectasis in the third quarter of 2025 is described as a major catalyst, with the potential to increase revenue once it reaches the market and begins generating sales late in Q3. The upcoming Phase II data for TPIP in PAH by mid-2025 and brensocatib in CRS without nasal polyps by the end of 2025 are highlighted as key clinical milestones that could influence future revenue streams if the results are positive.

Want to see how this story gets to that fair value? The narrative focuses on rapid revenue expansion, rising margins and a rich future earnings multiple. It is useful to understand which assumptions have the greatest impact on the model.

Result: Fair Value of $197.14 (UNDERVALUED)

However, Insmed’s story can change quickly if FDA review timelines slip or if payers push back on Brinsupri reimbursement, which could pressure revenue assumptions and earnings models.

Another View On Insmed’s Valuation

The narrative fair value of about $197 per Insmed share points to a large gap versus the current $131.10 price. Our DCF model is even more optimistic. It indicates Insmed is trading well below an estimated future cash flow value of $410.99, which implies a very different risk reward profile for long term holders.

That raises a practical question for you as an investor. Do you lean more on analyst earnings paths and multiples, or on long dated cash flow scenarios when you weigh what Insmed is worth today?

Next Steps

If this mixed picture of enthusiasm and concern around Insmed leaves you unsure, act quickly and dig into the underlying data and assumptions yourself. To see how the positives and negatives stack up in one place, take a closer look at the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Insmed?

If you are reassessing Insmed and want a broader watchlist, use screened ideas so you are not guessing and potentially missing stronger opportunities elsewhere.

• Kick start your search for potential high upside opportunities by reviewing screener containing 21 high quality undiscovered gems.
• Prioritise resilience by checking companies that score well on financial strength through the solid balance sheet and fundamentals stocks screener (48 results).
• Target stability with income potential by assessing reliable payers featured in the 8 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.